"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."
Cureus is on a mission to change the long-standing paradigm of medical publishing, where submitting research can be costly, complex and time-consuming.
tavi, tavr, transcatheter aortic valve replacement, transcatheter aortic valve implantation, stroke, prosthetic valve endocarditis, infective endocarditis
Suchapa Arayakarnkul , Koravich Lorlowhakarn, Sarinya Puwanant, Suphot Srimahachota, Aekarach Ariyachaipanich
Cite this article as: Arayakarnkul S, Lorlowhakarn K, Puwanant S, et al. (May 26, 2022) Infective Endocarditis Complicated With Septic Embolic Stroke After Transcatheter Aortic Valve Implantation: A Case Report. Cureus 14(5): e25379. doi:10.7759/cureus.25379
Transcatheter aortic valve implantation (TAVI) is a relatively novel procedure developed for aortic stenosis (AS) management in patients with moderate to high surgical risk, especially the elderly with multiple comorbidities. Infective endocarditis following transcatheter aortic valve implantation (post-TAVI-IE) is an uncommon complication that contributes to very high morbidity and mortality. Further complications from post-TAVI-IE include ischemic stroke from septic emboli. Here, we report a case of an 82-year-old man with severe symptomatic AS who underwent TAVI, presenting with fever and alteration of consciousness, which was diagnosed as post-TAVI-IE per Duke criteria complicated by acute hemiparesis from septic emboli stroke. He was treated successfully conservatively using antibiotics. We have reviewed the options of treatment and outcomes for post-TAVI-IE.
Aortic stenosis (AS) is a slowly progressive condition with increasing prevalence with advancing age and is one of the most commonly encountered valvular diseases worldwide. Once it produces symptoms such as dyspnea, chest pain, or heart failure, it is already in advanced stages. Transcatheter aortic valve replacement (TAVI) has been developed as a novel intervention to target elderly patients who hold moderate to high risks [1] to undergo surgical aortic valve replacement (SAVR) in severe stages, as defined by reduced valve area and high flow gradient across the aortic valve, and symptomatic AS patients with high risk for surgical intervention whose life expectancy is greater than one year [2].
Due to its less invasive nature, this fragile group of patients had a better chance of post-intervention recovery. Typical post-TAVI complications include permanent pacemaker implantation due to postoperative high-grade atrioventricular block, paravalvular regurgitation, and infection including infective endocarditis [3]. Infective endocarditis following transcatheter aortic valve implantation (post-TAVI-IE) is a serious complication with very high morbidity and mortality rates; 80% of the patients meet the criteria for surgical intervention and are reported to have a 75% mortality rate in one year [2,4]. This itself is a paradox since patients initially selected for TAVI procedures in the first place are the group that was previously deemed unfit for surgery. Therefore, despite a high proportion of patients having met the indication for surgical intervention, most cases were managed conservatively. Data on the mortality rates between surgical and conservative treatment have suggested the survival rates to be comparable [4,5], but the data is still very limited. There is still a gap in knowledge regarding the most appropriate course of action in the management of TAVI-IE.
Here, we report a case of an 82-year-old man with severe symptomatic AS who underwent TAVI, presenting with fever and alteration of consciousness, and was diagnosed as post-TAVI-IE per Duke criteria complicated by acute hemiparesis from a septic embolic stroke.
An 82-year-old patient with severe AS and ureteral stricture with nephrostomy who recently underwent TAVI presented with fever and alteration of consciousness. He had a history of fever for the past week, as confirmed by the body temperature of 38.3°C at presentation. Physical examination was notable for a diastolic murmur and valve clicks at the right parasternal border. No splinter hemorrhage, Janeway lesions, or Osler nodes were noted.
Three months prior to this presentation, the patient was diagnosed and treated for non-ST elevation acute coronary syndrome and severe calcific AS with acute heart failure. Due to high operative mortality risk as assessed with the Society of Thoracic Surgeons (STS) score of 9.7% (cut-off value for high risk = 8%), percutaneous coronary intervention (PCI) and TAVI were performed instead of open surgery.
During EvolutR #34 mm (Medtronic, Minneapolis, Minnesota) valve deployment, his electrocardiogram turned to a complete atrioventricular block, necessitating a permanent pacemaker insertion. Post-implantation ventriculography showed a well-seated aortic prosthesis with mild paravalvular leakage at 7 o’clock with no residual pressure gradient between the aorta and the left ventricle. The left ventricular ejection fraction was increased from 48% to 64%, and the patient was discharged.
During this subsequent admission, the initial workup for the source of fever revealed marked leukocytosis (16,170/μL, neutrophil 87.8%) and numerous white blood cells on urinalysis. Therefore, he was initially treated for urinary tract infection. On the third day of admission, the patient developed a sudden-onset right hemiparesis. Brain computed tomography confirmed an acute infarction in the left parietal area. A transesophageal echocardiogram (TEE) showed a 6 mm x 10 mm mobile mass at the anterior mitral leaflet with mitral regurgitation due to leaflet perforation, as shown in Video 1.
Infectious workup reported Enterococcus faecalis in both blood and urine cultures. Having met two major Duke criteria for IE, the patient was diagnosed with infective endocarditis after transcatheter aortic valve implantation (TAVI-IE) with septic embolic stroke. Considering septic emboli stroke complicating IE, our patient is indicated for surgery; nevertheless, taking into account the multiple comorbidities and high surgical risks, conservative treatment was decided upon. Antibiotics were switched to ampicillin and ceftriaxone. Following two weeks of intravenous antibiotics, he developed a new onset of fever. Blood culture was positive for Pseudomonas aeruginosa, which was thought to have been sourced from his nephrostomy. Intravenous ciprofloxacin was added to the regimen. A follow-up transthoracic echocardiogram (TTE) was done following four weeks of antibiotics, which showed a decreased size of the mitral valve vegetation at 4 mm x 8 mm. There is a newly seen 7-mm ventricular septal defect with left-to-right intracardiac shunt as shown as a high-velocity flow in the right ventricular chamber during systolic phase shown in Video 2.
All three antibiotics continued for the duration of six weeks. In the following year, the patient returned to the hospital due to episodes of pseudomonal septicemia, all of which were managed conservatively with six weeks of intravenous antibiotics. The source of infection was suspected to be his nephrostomy, which the multidisciplinary team meeting had recommended removal. To date, two years after TAVI, the patient is still alive and did not develop any additional complications.
This case demonstrates post-TAVI-IE in a severe AS patient who underwent TAVI and later developed septic embolic stroke as a further complication. Post-TAVI-IE [6] itself is described to affect 0.3%-1.2% of all patients who underwent the procedure [7]. Male gender (proposed to be owing to poor dental and urologic hygiene), chronic kidney disease (due to frequent intravascular manipulation from hemodialysis), and a new pacemaker implantation (as an entry route for pathogen and endocardial lesion during insertion procedure) are found to be associated with post-TAVI-IE.
Diagnosis of post-TAVI-IE utilizes the modified Duke criteria [8]. The most common presentations are fever and heart failure [5], usually presenting within one-year post-procedure. The median time is at 5.4 months. Most frequently isolated causative organisms are gram-positive bacteria such as streptococcus (25.3%), staphylococci (25.3%), and enterococci (24.1%), with Enterococcus spp. as a leading cause in patients who had undergone the transfemoral catheter route [9]. The all-cause mortality of post-TAVI-IE has been reported to be as considerable at 75% one year after diagnosis [2].
Post-TAVI-IE may lead to various complications such as structural destruction (valvular regurgitation or ventricular septal defect), uncontrolled infection, or stroke. Risk factors for septic embolic stroke after TAVI include previous stroke (either at baseline or periprocedural TAVI stroke), residual aortic regurgitation more than or equal to moderate after TAVI, balloon-expandable valves, infective endocarditis within 30 days after TAVI, and vegetation size of more than 8 mm, especially those involving mitral valve. Incidence of stroke was reported to be at 6%-60% among those who underwent the procedure, with a higher probability in those with more risk factors. Mortality rates for this patient group were reported at 66% at one year [6].
Management of post-TAVI-IE and the following septic embolic stroke is a challenging medical dilemma. Persistent infection, uncontrolled embolism, or refractory heart failure may indicate an open-heart surgery [5,9], which was initially avoided in this group of patients who are deemed at high risk to undergo an operation. Therefore, despite having met indications for open-heart surgery, most patients were managed conservatively with antibiotics [10]. Previous literature on mortality rates comparing conservative and surgical management is still inconclusive. Some studies suggested the mortality rates are of no significant difference [4,5], while a meta-analysis reported a logistic regression model showing surgical treatment with self-expandable devices to relate to lower mortality [9]. Proposed management regarding post-TAVI-IE is shown in Table 1 with advantages and disadvantages of each modality, which include surgical intervention, conservative management, and very rarely, a TAVI-in-TAVI regarding post-TAVI-IE management [11].
Post-TAVI-IE is a serious complication following TAVI. This not uncommon complication leads to extensive morbidity and mortality. To date, no consensus management has been concerted. Since this patient population is very vulnerable to decompensation, the best effort should go toward its prevention. Nevertheless, in the event that post-TAVI-IE ensues, the most appropriate course of action varies, and individualized strategy should be discussed among the involved cardiovascular personnel and multidisciplinary team as deemed most fit to each patient’s distinctive setting.
Internal Medicine, Chulalongkorn University, Bangkok, THA
Internal Medicine, Chulalongkorn University, Bangkok, THA
Cardiovascular Medicine, Chulalongkorn University, Bangkok, THA
Cardiovascular Medicine, Chulalongkorn University, Bangkok, THA
Cardiology, King Chulalongkorn Memorial Hospital, Bangkok, THA
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Arayakarnkul S, Lorlowhakarn K, Puwanant S, et al. (May 26, 2022) Infective Endocarditis Complicated With Septic Embolic Stroke After Transcatheter Aortic Valve Implantation: A Case Report. Cureus 14(5): e25379. doi:10.7759/cureus.25379
Peer review began: April 29, 2022 Peer review concluded: May 23, 2022 Published: May 26, 2022
© Copyright 2022 Arayakarnkul et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. Learn more here.
This link will take you to a third party website that is not affiliated with Cureus, Inc. Please note that Cureus is not responsible for any content or activities contained within our partner or affiliate websites.
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. SIQ™ assesses article importance and quality by embracing the collective intelligence of the Cureus community-at-large. All registered users are invited to contribute to the SIQ™ of any published article. (Authors cannot rate their own articles.)
High ratings should be reserved for work that is truly groundbreaking in its respective field. Anything above 5 should be considered above average. While all registered Cureus users can rate any published article, the opinion of domain experts is weighted appreciably more than that of non-specialists. An article’s SIQ™ will appear alongside the article after being rated twice and is recalculated with each additional rating.
Visit our SIQ™ page to find out more.
Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. SIQ™ assesses article importance and quality by embracing the collective intelligence of the Cureus community-at-large. All registered users are invited to contribute to the SIQ™ of any published article. (Authors cannot rate their own articles.)
Already have an account? Sign in.
Please note that by doing so you agree to be added to our monthly email newsletter distribution list.
By joining Cureus, you agree to our Privacy Policy and Terms of Use.